Currently, there are 160.02M common shares owned by the public and among those 155.19M shares have been available to trade.
The company’s stock has a 5-day price change of -13.76% and -59.66% over the past three months. IRWD shares are trading -57.56% year to date (YTD), with the 12-month market performance down to -87.38% lower. It has a 12-month low price of $1.59 and touched a high of $15.70 over the same period. IRWD has an average intraday trading volume of 2.87 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -36.76%, -47.37%, and -62.19% respectively.
Institutional ownership of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) shares accounts for 101.12% of the company’s 160.02M shares outstanding.
It has a market capitalization of $300.85M and a beta (3y monthly) value of 0.33. The earnings-per-share (ttm) stands at -$0.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.72% over the week and 10.76% over the month.
Earnings per share for the fiscal year are expected to increase by 101.20%, and 117.55% over the next financial year.
Looking at the support for the IRWD, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on September 09, 2024, with the firm’s price target at $5. CapitalOne coverage for the Ironwood Pharmaceuticals Inc (IRWD) stock in a research note released on August 08, 2024 offered a Equal Weight rating with a price target of $4. Craig Hallum was of a view on January 17, 2024 that the stock is Buy, while Wells Fargo gave the stock Overweight rating on December 14, 2023, issuing a price target of $20. Jefferies on their part issued Buy rating on November 09, 2023.
